Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 3
2013 1
2014 1
2015 1
2016 2
2018 3
2019 1
2020 1
2023 1
2024 2
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Off-Label Use of Clozapine in Children and Adolescents-A Literature Review.
Rachamallu V, Elberson BW, Vutam E, Aligeti M. Rachamallu V, et al. Am J Ther. 2019 May/Jun;26(3):e406-e416. doi: 10.1097/MJT.0000000000000894. Am J Ther. 2019. PMID: 31082865 Review.
BACKGROUND: Clozapine is a second-generation antipsychotic typically used for refractory schizophrenia or otherwise psychotic pathology. There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. We investigated the current state of re …
BACKGROUND: Clozapine is a second-generation antipsychotic typically used for refractory schizophrenia or otherwise psychotic patholo …
Off-label Prescribing of Clozapine and Safety.
Divac N, Jakovčevski I. Divac N, et al. Turk Psikiyatri Derg. 2025;36:53. doi: 10.5080/u27655. Turk Psikiyatri Derg. 2025. PMID: 41070513 Free PMC article. Review.
Clozapine, even at relatively low doses, has shown potential clinical benefits in patients with bipolar disorder, borderline personality disorder, and post-traumatic stress disorder. ...Despite these risks, with careful patient selection, individualized dosing, and continu …
Clozapine, even at relatively low doses, has shown potential clinical benefits in patients with bipolar disorder, borderline personal …
Beyond the Off-Label: A Systematic Review of What We Know About Clozapine Use for Children.
Pimenta de Figueiredo T, de Almeida IR, de Freitas FAC, Kubrusly CHC, Alvim-Soares Júnior AM, de Miranda DM. Pimenta de Figueiredo T, et al. J Child Adolesc Psychopharmacol. 2024 Nov;34(9):e419-e426. doi: 10.1089/cap.2024.0070. Epub 2024 Sep 30. J Child Adolesc Psychopharmacol. 2024. PMID: 39344799
However, there are limited data on the use of clozapine in children, and no systematic review has addressed its use in this population. ...Conclusion: Further high-quality research is needed to establish precise guidelines for using clozapine in children....
However, there are limited data on the use of clozapine in children, and no systematic review has addressed its use in this populatio …
Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
Maher AR, Theodore G. Maher AR, et al. J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. doi: 10.18553/jmcp.2012.18.s5-b.1. J Manag Care Pharm. 2012. PMID: 22784311 Free PMC article.
Beginning in 2006, 9 atypical antipsychotic drugs have been approved by the FDA for indications that were previously off-label uses: aripiprazole (as augmentation for major depressive disorder [MDD] and for autism spectrum disorders), asenapine, clozapine, iloperidone, ola …
Beginning in 2006, 9 atypical antipsychotic drugs have been approved by the FDA for indications that were previously off-label uses: aripipr …
Off-label second generation antipsychotics for impulse regulation disorders: a review.
Scheltema Beduin A, de Haan L. Scheltema Beduin A, et al. Psychopharmacol Bull. 2010;43(3):45-81. Psychopharmacol Bull. 2010. PMID: 21150846 Review.
In this review we describe the evidence that supports off-label use of the second generation antipsychotics risperidone, olanzapine, clozapine, ziprasidone, quetiapine and aripiprazole in impulse regulation disorders and substance abuse disorders. ...In tic disorders two d …
In this review we describe the evidence that supports off-label use of the second generation antipsychotics risperidone, olanzapine, cloz …
Off-label use of antipsychotic medications in Medicaid.
Leslie DL, Rosenheck R. Leslie DL, et al. Am J Manag Care. 2012 Mar 1;18(3):e109-17. Am J Manag Care. 2012. PMID: 22435962 Free article.
Off-label use was most common among patients receiving risperidone and least common among patients receiving clozapine. CONCLUSIONS: Off-label use of antipsychotic medications is common, particularly among the elderly and children/adolescents. ...
Off-label use was most common among patients receiving risperidone and least common among patients receiving clozapine. CONCLUSIONS: …
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM. Black KJ, et al. CNS Spectr. 2018 Dec;23(6):402-413. doi: 10.1017/S1092852918001359. CNS Spectr. 2018. PMID: 30588905 Review.
Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for managemen …
Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine …
17 results